Dexcom Inc (DXCM) Company Profile & Statistics

Dexcom Inc
DXCM
(Nasdaq - US)
Closed
74.44
-0.80 (-1.06%)
in:usd•As of: Nov 21, 2024 15:59 UTC -5
After Market:74.51+0.07 (+0.09%)
Open
75.11
High
75.70
Low
74.17

About Dexcom Inc

CEO

Kevin R. Sayer

Headquarters

6340 sequence drive

san diego, ca 92121, united states

Auditor

Ernst & Young LLP

Employees

9,600

Share Holders

Website

www.dexcom.com

Industry

medical specialties

Sector

health technology

Company Overview

DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients. A key element of DexCom's monitoring system technology is the continuous measure of patient's blood glucose level and transmission of that information to a small cell phone-sized receiver in real time. The company's monitoring systems aim to provide real-time continuous blood glucose values, trend data and alerts to assist patients in managing their blood glucose levels.

Dexcom Inc Statistics

Valuation Measures

Market Capitalization ²	29.08B
Enterprise Value	30.89B
Enterprise Value/EBITDA (ttm)	36.76
Price to Earnings Ratio (ttm)	44.05
Price to Book (mrq)	14.78
Price to Sales (ttm)	7.40
Price to Cash (ytd)	36.19

Profitability

Gross Margin (ttm)	61.65%
Operating Margin (ttm)	17.33%
Profit Margin (ttm)	17.12%
Return on Equity (ttm)	31.40%
Return on Invested Capital (ttm)	14.81%
Return on Assets (ttm)	10.58%

Income Statement

Revenue (ttm)	3.95B
Revenue Per Share (ttm)	10.12
Gross Profit (ttm)	2.44B
EBITDA (ttm)³	840.40M
Net Income Avi to Common (ttm)	680.80M
Diluted EPS (ttm)	1.67

Share Statistics

Beta (5Y Monthly)	1.17
52-Week Change	-31.68%
S&P500 52-Week Change	30.55%
S&P500 Member	Yes
Stock Optionable	Yes
Total Shares Outstanding ¹	390.60M
Dividend Yield	0.00%
Float ⁴	389.42M
% Held by Insiders	0.30%
% Held by Institutions	97.75%

Balance Sheet

Total Cash (mrq)	2.49B
Total Cash Per Share (mrq)	6.38
Total Debt (mrq)	2.44B
Total Debt/Equity (mrq)	123.27%
Current Ratio (mrq)	2.46%
Quick Ratio (mrq)	2.12%
Book Value Per Share (mrq)	5.07

Cash Flow

Operating Cash Flow Per Share (ytd)	1.68
Free Cash Flow (ytd)	453.90M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Dexcom Inc

Trade With A Regulated Broker